about
Structural analysis of human glutamine:fructose-6-phosphate amidotransferase, a key regulator in type 2 diabetesDesigning inhibitors of M2 proton channel against H1N1 swine influenza virusInsights from modeling the 3D structure of New Delhi metallo-β-lactamse and its binding interactions with antibiotic drugsNovel inhibitor design for hemagglutinin against H1N1 influenza virus by core hopping methodDesign novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approachChanges in the metabolic profile of rat liver after α-tocopherol deficiency as revealed by metabolomics analysis.Inactivation of glucosamine-6-phosphate synthase by N3-oxoacyl derivatives of L-2,3-diaminopropanoic acid.(6R,9S)-6"-(4"-hydroxybenzoyl)-roseoside, a new megastigmane derivative from Ouratea polyantha and its effect on hepatic glucose-6-phosphatase.Signal propagation in protein interaction network during colorectal cancer progression.Thermogenic and metabolic antiobesity drugs: rationale and opportunities.An in silico study on antidiabetic activity of bioactive compounds in Euphorbia thymifolia Linn.Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives.High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma.Identification of potential CCR5 inhibitors through pharmacophore-based virtual screening, molecular dynamics simulation and binding free energy analysis.Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.Functional domains and interdomain communication in Candida albicans glucosamine-6-phosphate synthase.Study of human dopamine sulfotransferases based on gene expression programming.Investigation into potent inflammation inhibitors from traditional Chinese medicine.Glutamine: fructose-6-phosphate amidotransferase (GFAT): homology modelling and designing of new inhibitors using pharmacophore and docking based hierarchical virtual screening protocol.Modelling the molecular mechanism of protein-protein interactions and their inhibition: CypD-p53 case study.Predicting subcellular location of apoptosis proteins with pseudo amino acid composition: approach from amino acid substitution matrix and auto covariance transformation.GPCR-2L: predicting G protein-coupled receptors and their types by hybridizing two different modes of pseudo amino acid compositions.The small-molecule inhibitor selectivity between IKKα and IKKβ kinases in NF-κB signaling pathway.A Comprehensive In Silico Method to Study the QSTR of the Aconitine Alkaloids for Designing Novel Drugs
P2860
Q27653066-9F0501F8-D35C-48C1-B3D5-4B6066F3616CQ28473007-A289554A-9185-46FA-861D-81974F5CEF92Q28477703-284DDA2C-0B29-423E-A4C6-7F5920613495Q28478196-0E8AE3EA-27AB-4888-8399-0A97F4B06965Q28484141-D4A66DE5-85AF-4437-9585-FF95696B37FFQ33933317-A6053170-6200-4C96-8B16-D2124231EF1AQ34085476-C5D34CBF-3E8B-413B-81CD-AD50CE936728Q36242728-2949B2D8-5500-4F4F-991B-475748F1AE6DQ36737842-FF1A996F-1525-43D3-8F50-C503A38A053FQ36772888-E8E8AEBE-F694-4D26-AAEA-4EFEA2DB5D87Q37187998-1489FF13-15F8-4932-B3E8-B62BED5A8E49Q37693855-F6A4E6AE-3608-4722-B2BB-A835DC63759FQ37745961-59C3F1F8-769F-4062-864F-29F8C45F0F64Q39314390-2F55FAD4-5451-46E8-80D2-904AC7F9599BQ39771912-59EB7AEC-FB15-4FD4-A89D-C2E6C863CC0BQ42791201-8DA0AAA5-913B-4E8A-9C88-FECBEEE42831Q43974588-111AD306-A233-4D8D-BB95-2FB5D3EAAD32Q47278490-A4F2A7E6-46DD-4D69-8385-F285457FBD76Q50907551-229C062A-BD2A-4CC7-B93C-51D459029C77Q50955211-E399D3A1-F3C6-4099-9432-A364E40CDCA6Q51600112-A4ADB7D6-72BD-4F9D-9905-CB72D803009CQ51621902-1640AE21-001E-4C86-B717-17B8E0BCF7F5Q53393935-88226E33-27EF-479A-BC1C-55E4C11373AAQ58696412-F867B90F-C79C-46FD-8295-434BE375C9C4
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականին հրատարակուած գիտական յօդուած
@hyw
2004 թվականին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Molecular therapeutic target for type-2 diabetes
@ast
Molecular therapeutic target for type-2 diabetes
@en
Molecular therapeutic target for type-2 diabetes
@nl
type
label
Molecular therapeutic target for type-2 diabetes
@ast
Molecular therapeutic target for type-2 diabetes
@en
Molecular therapeutic target for type-2 diabetes
@nl
prefLabel
Molecular therapeutic target for type-2 diabetes
@ast
Molecular therapeutic target for type-2 diabetes
@en
Molecular therapeutic target for type-2 diabetes
@nl
P3181
P356
P1476
Molecular therapeutic target for type-2 diabetes
@en
P304
P3181
P356
10.1021/PR049849V
P407
P577
2004-01-01T00:00:00Z